BCMA TNFRSF17 hFc Chimera, Human
BCMA TNFRSF17 HFc Chimera, Human

The purity of BCMA/TNFRSF17 hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

BCMA TNFRSF17 HFc Chimera, Human

BCMA/TNFRSF17 hFc Chimera, Human on SDS-PAGE under reducing and non-reducing conditions. The purity is greater than 95%.

BCMA TNFRSF17 HFc Chimera, Human

Immobilized BAFF/TNFSF13B/CD257[Biotin], His & Avi, Human (Cat. No.Z04413) at 1 μg/mL (100 μL/well) on the plate. Dose response curve for BCMA/TNFRSF17 hFc Chimera, Human (Cat. No.Z06800) with the EC50 of 1.62 ng/ml determined by ELISA.

BCMA TNFRSF17 HFc Chimera, Human

Immobilized BCMA/TNFRSF17 hFc Chimera, Human (Cat. No.Z06800) at 1 μg/mL (100 μL/well) can bind Anti-Human BCMA antibody.

BCMA TNFRSF17 hFc Chimera, Human

B-cell maturation antigen (BCMA or BCM), also known as tumor necrosis factor receptor superfamily member 17 (TNFRSF17), is a protein that in humans is encoded by the TNFRSF17 gene.TNFRSF17 is a cell surface receptor of the TNF receptor superfamily which recognizes B-cell activating factor (BAFF).
Z06800
¥55,075.00

Ask us a question
Product Introduction
Species Human
Protein Construction
BCMA/TNFRSF17 (Met1-Ala54)
Accession # Q02223-1		 hFc
N-term C-term
Purity ≥ 95% as analyzed by reducing SDS-PAGE
Endotoxin Level < 0.2 EU/μg of protein by gel clotting method
Biological Activity Immobilized Human BAFF/TNFSF13B/CD257, His at 1 μg/ml (100μl/well) on the plate can bind BCMA/TNFRSF17 hFc Chimera, Human (Cat.No.: Z06800).
Theoretical Molecular Weight 31.4 kDa
Apparent Molecular Weight Due to glycosylation and dimerization, the protein migrates to 70 kDa based on SDS-PAGE result.
Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH7.2
Reconstitution Reconstitute the lyophilized powder with deionized water (or equivalent) to a final concentration of 0.5 mg/ml.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples
  • BCMA TNFRSF17 HFc Chimera, Human
    • BCMA TNFRSF17 HFc Chimera, Human

    The purity of BCMA/TNFRSF17 hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

  • BCMA TNFRSF17 HFc Chimera, Human
    • BCMA TNFRSF17 HFc Chimera, Human

    BCMA/TNFRSF17 hFc Chimera, Human on SDS-PAGE under reducing and non-reducing conditions. The purity is greater than 95%.

  • BCMA TNFRSF17 HFc Chimera, Human
    • BCMA TNFRSF17 HFc Chimera, Human

    Immobilized BAFF/TNFSF13B/CD257[Biotin], His & Avi, Human (Cat. No.Z04413) at 1 μg/mL (100 μL/well) on the plate. Dose response curve for BCMA/TNFRSF17 hFc Chimera, Human (Cat. No.Z06800) with the EC50 of 1.62 ng/ml determined by ELISA.

  • BCMA TNFRSF17 HFc Chimera, Human
    • BCMA TNFRSF17 HFc Chimera, Human

    Immobilized BCMA/TNFRSF17 hFc Chimera, Human (Cat. No.Z06800) at 1 μg/mL (100 μL/well) can bind Anti-Human BCMA antibody.


Background
Target Background BCMA (B-cell maturation antigen), also called TNFRSF17, is encoded by the TNFRSF17 gene. It acts as a cell surface receptor of the TNF receptor superfamily. BCMA recognizes B-cell activating factor (BAFF). It interacts with the B-cell activating factor TNFSF13B.
Synonyms CD269; TNFRSF17; BCMA; BCM; TNFRSF13A

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.